Head-to-head evidence
Alirocumab vs Ebronucimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals
NCT01507831 · Phase 3 · completed
The study was large (2,341 participants), randomized, quadruple-blind, and placebo-controlled. Its primary clinical safety endpoint was reported, but the registry does not provide a statistical significance test for the comparison, so whether the primary endpoint was met cannot be determined.
Next expected readout: December 2026 · NCT07477704 (registry estimate)
Ebronucimab
Developed by Akeso
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. However, its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome, and the registry does not report whether the comparison was favorable or statistically significant.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Ebronucimab's landscape